Jan 22, 2025, 11:03
Final Overall Survival in the Phase III FALCON Trial
Kristina Jankovic, Medical Oncology Resident at the University Clinical Center Niš, shared an article by John F.R. Robertso on X:
“Final OS analysis from FALCON:
- No significant difference between fulvestrant (44.8 months) and anastrozole (42.7 months) in ET-naive HR+ ABC.
- 15% risk of death with fulvestrant in nonvisceral disease (65.2 vs. 47.8 months).”
Fulvestrant Versus Anastrozole in Endocrine Therapy–Naïve Women With Hormone Receptor–Positive Advanced Breast Cancer: Final Overall Survival in the Phase III FALCON Trial.
Authors: John F.R. Robertso, et al.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Jan 22, 2025, 11:05
Jan 22, 2025, 11:03
Jan 22, 2025, 10:59
Jan 22, 2025, 10:40
Jan 22, 2025, 10:28